8-K 1 v202990_8k.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
FORM 8-K
 
CURRENT REPORT 
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported: November 17, 2010): November 19, 2010

 
ALTEROLA BIOTECH INC.
(Exact name of registrant as specified in its charter)

 
Nevada
  
333-156091
  
N/A
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
 
228 Hamilton Avenue, 3rd Floor
Palo Alto, California
  
94301
 
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: +45-8842 9181
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
Forward Looking Statements
 
This Form 8-K and other reports we file from time to time with the Securities and Exchange Commission (collectively the "Filings") contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made by our management. When used in the Filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to us or our management identify forward looking statements. Such statements reflect our current view with respect to future events and are subject to risks, uncertainties, assumptions and other factors (including the risks contained in the Filings) relating to our industry and our operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
 
Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements and except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. The following discussion should be read in conjunction with the exhibits attached to this Current Report on Form 8-K.

 
2
 

Item 1.01             Entry into a Material Definitive Agreement.
 
On November 17, 2010, Soren Nielsen (“Nielsen”), the President and director of Alterola Biotech Inc. (the “Company”) entered into a cancelation agreement with the Company (the “Agreement”) pursuant to which Nielsen agreed to cancel an aggregate of 40,000,000 shares of common stock of the Company (the “Common Stock”)  owned by him.  As consideration for the Agreement, the Company agreed to issue to Nielsen options to purchase shares of Common Stock pursuant to a Company option plan which the Company expects to adopt, in such number as shall in the future be determined by the Company’s board of directors.
 
Item 9.01             Financial Statements and Exhibits.
 
(d)
Exhibits.
 
10.1
Cancelation Agreement between Soren Nielsen and the Company, dated November 17, 2010.

 
3
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:   November 19, 2010
 ALTEROLA BIOTECH INC.  
       
 
By:
/s/ Soren Nielsen
  
   
Name: Soren Nielsen
  
   
Title: Chief Executive Officer
  
 
 
4